Indaptus Therapeutics, Inc. Capital Expenditures
Indaptus Therapeutics, Inc. (INDP) reported Capital Expenditures of $3.85 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-17.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2023-03-17
- Indaptus Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2021-12-31 was $0.00.
- Indaptus Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2021-09-30 was $1.65K.
- Indaptus Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2021 was $3.85K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $1.65K derived: sum of 2 quarters · filed 2023-03-17 | $3.85K 10-K · filed 2023-03-17 | |
| 2021-09-30 | $1.65K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $3.85K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $2.20K 10-Q · filed 2022-08-08 | |||
| 2020-06-30 | $3.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |